| Listed site | cro | cro |
|---|
| Summary | Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making. | Leading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers. |
|---|
| Services | - Biostatistics & Statistical Programming
- Data Management & eClinical
- Regulatory Affairs
- Medical Writing
- Computational & In-Silico Drug Discovery
- Translational Research
- Target Identification & Validation
- High-Throughput Screening
- Medicinal Chemistry
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Genetic Toxicology
- Discovery Research
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Preclinical In Vitro Studies
- Preclinical In Vivo Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Phase I Clinical Trials
- Biomarker Assays
- Phase II Clinical Trials
- Phase III Clinical Trials
- Clinical Operations
- Phase IV / Post-Marketing
- US FDA Regulatory Strategy
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- China NMPA Regulatory Strategy
- Clinical Trial Services
| - Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Clinical Trial Services
- Clinical Imaging Core Lab
- Central Laboratory Services
- Medical Writing
- Pharmacovigilance & Drug Safety
- Biostatistics & Statistical Programming
- Data Management & eClinical
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- China NMPA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- Device & Combination Product Services
- Translational Research
- GLP Toxicology
- In Vitro ADME / DMPK
- In Vitro Pharmacology
- Preclinical In Vitro Studies
- In Vivo PK / PD Studies
- In Vivo Efficacy Models
- Preclinical In Vivo Studies
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Medicinal Chemistry
- High-Throughput Screening
- Oncology Specialty Services
- Cardiovascular & Metabolic Specialty Services
- CNS Specialty Services
- Immunology & Inflammation Services
- Virology Services
- Microbiology Services
|
|---|
| Modalities | - Small Molecule
- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Biologics (Other)
- Peptide
- Peptide
- Oligonucleotide
- Oligonucleotide
- mRNA
- mRNA
- Antibody-Drug Conjugate (ADC)
- Antibody-Drug Conjugate (ADC)
- Gene Therapy
- Gene Therapy
- Cell Therapy
- Cell Therapy
- Vaccine
- Vaccine
| - Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Vaccine
- Cell Therapy
- Gene Therapy
- Radiopharmaceutical
- Oligonucleotide
- Peptide
|
|---|
| Indications | - Oncology
- Rare Disease
- Immunology
- Immunology
- Neurology
- Neurology
- Psychiatry
- Metabolic
- Metabolic
- Cardiovascular
- Cardiovascular
- Infectious Disease
- Infectious Disease
- Respiratory
- Respiratory
- Dermatology
- Dermatology
- Ophthalmology
- Ophthalmology
- Gastroenterology
- Gastroenterology
- Nephrology
- Nephrology
- Women's Health
- Women's Health
| - Oncology
- Cardiovascular
- Neurology
- Immunology
- Infectious Disease
- Rare Disease
- Metabolic
- Ophthalmology
- Gastroenterology
- Respiratory
|
|---|
| Locations | - Global network
- Global presence, 30 countries
- Global presence, Multiple, 30 countries, Global
- Global presence, Multiple, 30+ countries
- Global presence, Multiple, 30 countries, International
- Headquarters, Radnor, Pennsylvania, United States
- Global presence, 30 countries
- Global presence, 30+ countries
| - Headquarters, Hangzhou, Zhejiang, China
- Global Offices, Multiple, Global, Multiple (180+ locations across 5 continents)
|
|---|
| Certifications | Data not yet provided. | Data not yet provided. |
|---|
| Reviews | Review summary appears after site-level review signal gate opens. | Review summary appears after site-level review signal gate opens. |
|---|